---
layout: post
title: "Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; EYLEA HD (aflibercept)"
date: 2026-02-04 21:51:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-06969
original_published: 2025-04-23 00:00:00 +0000
significance: 8.00
---

# Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; EYLEA HD (aflibercept)

**Published:** February 04, 2026 21:51 UTC
**Source:** Federal Register
**Original Published:** April 23, 2025 00:00 UTC
**Document Number:** 2025-06969

## Summary

The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat medical countermeasure (MCM) product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the application for EYLEA HD (aflibercept), approved August 18, 2023, meets the criteria for redeeming a priority review voucher.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/04/23/2025-06969/notice-of-approval-of-product-under-voucher-material-threat-medical-countermeasure-priority-review)
- API: https://www.federalregister.gov/api/v1/documents/2025-06969

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
